Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association (HCMA), the leading advocacy group representing patients and families affected by hypertrophic cardiomyopathy. The partnership will accelerate patient recruitment and engagement in the ongoing Fortitude-HCM study, a Phase 2b clinical trial evaluating ninerafaxstat in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), a debilitating disease with no currently approved treatments. Ninerafaxstat is a novel investigational therapy designed to optimize mitochondrial energy production in heart muscle cells without adverse impact on left ventricular ejection fraction, heart rate or blood pressure.
HCMA will support trial recruitment by educating the HCM community about the Fortitude-HCM study. This includes promoting awareness through its outreach programs, conferences, patient communications, and surveys, to help connect patients and clinicians with trial information and enrollment resources. The Fortitude-HCM study will also be highlighted at the upcoming HCMA Annual Patient Meeting on October 18, 2025, of which Imbria is a sponsor.
“Every step forward in clinical research brings us closer to improving the lives of those living with nHCM,” said Lisa Salberg, founder and CEO, HCMA. “By supporting patient recruitment for Fortitude-HCM and spotlighting this collaboration at our annual meeting, we aim to increase awareness of this potential treatment and connect patients and families with meaningful opportunities to advance research and improve care.”
“Initiating the Fortitude-HCM trial to evaluate ninerafaxstat for nHCM represents a major milestone for Imbria and further validates our commitment to patients and families affected by this disease,” said Alvin Shih, MD, Imbria’s Chief Executive Officer. “We are proud supporters of the HCMA and its dedicated work on behalf of this patient community, and we look forward to working with Lisa and her team to accelerate the development of therapies for nHCM.”
For more information please visit www.imbria.com and www.4hcm.org
May 28, 2026 
